No Abstract

Section snippets Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention 2073Renato D. Lopes, Steven J. Atlas, Alan S. Go, Steven A. Lubitz, David D. McManus, Rowena J. Dolor, Ranee Chatterjee, Michael B. Rothberg, David R. Rushlow, Lori A. Crosson, Ronald S. Aronson, Michael Patlakh, Dianne Gallup, Donna J. Mills, Emily C. O’Brien, Daniel E. SingerAlthough randomized trials using

Section snippets Funding Support and Author DisclosuresThe authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Section snippets Serving the Cardiovascular Community: The Power of IntegrationOur goal is simple but transformative: to better serve the cardiovascular community by delivering the highest-quality content in a more integrated and efficient manner. Readers care more about the science than the specific journal in which it appears. By coordinating our efforts across JACC and JACC: Clinical Electrophysiology

Section snippets The Landscape of Cardiovascular Employment ModelsThere are roughly 6 distinct types of employment models in today’s cardiovascular practice landscape, spanning from the more traditional models of independent practice and academic medicine to newer integrated health system models and private equity-backed ventures. Recognizing Nonclinical Competencies in Clinical PracticeRegardless

Section snippets MethodsThe VIVA (Viborg Vascular) trial is a population-based, randomized controlled trial of men age 65 to 74 years, who were randomized 1:1 to vascular screening or to no screening. Allocation was based on computer-generated random numbers and stratified into 19 municipalities. Only the control group was masked. In VIVA, AAA was defined as an aortic diameter ≥30 mm measured by 2-dimensional

Section snippets Funding Support and Author DisclosuresDr Butala has received grants from the American Heart Association and the Boettcher Foundation; has received consulting fees from Shockwave Medical, Boston Scientific, Catch Bio, and HiLabs; has an ownership interest in Catch Bio and HiLabs; and has received food/beverages from Medtronic and Edwards. Dr Krishnaswamy has reported that he has no

No Abstract

No Abstract

Section snippets Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program 1979Milton Packer, João Pedro Ferreira, Javed Butler, Gerasimos Filippatos, James L. Januzzi, Jr, Sandra González Maldonado, Marina Panova-Noeva, Stuart J. Pocock, Jürgen H. Prochaska, Maral Saadati, Naveed Sattar, Mikhail Sumin

BackgroundCurrently available antiproprotein convertase subtilisin/kexin type 9 monoclonal antibodies can effectively decrease low-density lipoprotein cholesterol (LDL-C) levels, but require frequent dosing. Recaticimab is a novel humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9. In a phase 1b/2 trial, recaticimab as add-on to stable statins showed robust LDL-C reduction

Randomized clinical trials are the gold standard for establishing the efficacy and safety of cardiovascular therapies. However, current pivotal trials are expensive, lengthy, and insufficiently diverse. Emerging artificial intelligence (AI) technologies can potentially automate and streamline clinical trial operations. This review describes opportunities to integrate AI throughout a trial’s life cycle

The delayed and modest uptake of evidence-based treatments following cardiovascular clinical trials highlights the need for greater attention to implementation early in the development and testing of treatments. However, implementation science is not well understood and is often an afterthought following phase 3 trials. In this review, we describe the goals, frameworks, and methods of implementation

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

No Abstract

Section snippets Funding Support and Author DisclosuresDr Ali has received institutional grants from Abbott, Abiomed, Acist Medical, Boston Scientific, Cardiovascular Systems, Medtronic, Opsens Medical, Philips, and Shockwave Medical; has received personal fees from Amgen, AstraZeneca, and Boston Scientific; and owns equity in Elucid, Lifelink, Spectrawave, Shockwave, and Vital Connect. Dr Yong has

No Abstract

No Abstract

1773

BackgroundStandard-of-care (SoC) medications for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) are recommended as first-line therapy despite the lack of evidence from controlled clinical trials and well known off-target side effects. ObjectivesWe describe the impact of SoC therapy downtitration and withdrawal in patients already receiving aficamten in FOREST-HCM (Follow-Up, Open-Label

“Standard treatment: one that you must consider when NOT to use, rather than when to use.”—Claudio Rapezzi

No Abstract

BackgroundTricuspid regurgitation (TR) is a right-sided valvular disease independently associated with morbidity and mortality. The TRILUMINATE Pivotal trial is the first randomized, controlled trial assessing the impact of TR reduction with tricuspid transcatheter edge-to-edge repair (T-TEER). ObjectiveOutcomes from the full randomized cohort of the TRILUMINATE Pivotal trial have not been previously

BackgroundTricuspid valve transcatheter edge-to-edge repair has emerged as a valuable treatment option for patients with severe tricuspid regurgitation (TR). ObjectivesThis study aims to investigate the safety and effectiveness of the PASCAL transcatheter valve repair system in treating severe TR in a real-world patient population. MethodsThe PASTE (PASCAL for Tricuspid Regurgitation—a European registry)

No Abstract

BackgroundFinerenone has kidney protective effects in patients with chronic kidney disease (CKD) with type 2 diabetes, but effects on kidney outcomes in patients with heart failure (HF) with and without diabetes and/or CKD are not known. ObjectivesExamine the effects of finerenone on kidney outcomes in FINEARTS-HF, a randomized trial of finerenone vs. placebo among patients with HF with mildly reduced

Section snippets Funding Support and Author DisclosuresThe authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Section snippets MethodsWe used a time-stratified case-crossover design by selecting the control date on the same day of the week as the case within the same calendar month, to control for day of week, seasonality, and long-term trends, in addition to time-invariant confounders.We obtained the cohort data (2016-2022) from the Blue Cross Blue Shield (BCBS) Association—the largest U.S. commercial insurance

Section snippets Funding Support and Author DisclosuresFunding support was provided by The MGH Heart Failure Research Innovation Fund and Jeffrey and Mary Ellen Jay Chair in Heart Failure. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

No Abstract

Low-dose aspirin remains the most commonly used antiplatelet agent among patients with atherosclerotic cardiovascular disease. Aspirin hypersensitivity occurs in 1% to 5% of patients and is among the most frequent causes for prohibiting the use of aspirin, posing a significant dilemma on how to manage these patients in clinical practice. Aspirin hypersensitivity is often misinterpreted and confused

Section snippets Funding Support and Author DisclosuresDr Neuen is supported by an Australian National Health and Medical Research Council Emerging Leader Investigator Grant (grant number 2026621) and a Ramaciotti Foundation Health Investment Grant (grant number 2023HIG69). Dr Arnott is supported by a Medical Research Future Fund Investigator Grant. The funders had no role in the writing of the manuscript

No Abstract